Rare disease biotech raises $47M Series C, plans for Phase 2 trial
Summary
Cam\xadbridge, UK-based Healx has pulled in $47 mil\xadlion in a Se\xadries C round and has nabbed IND clear\xadance from the FDA to run its first Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected